Antibodies, bispecifics and CAR-T cells: how they work and their emergencies (CRS, ICANS)
- Treatment and support
New treatments turn the immune system against blood cancers. They can work when chemotherapy fails, but they can set off a dangerous fever storm.
What it is
Three families use the immune system against blood cancers. Monoclonal antibodies bind a surface marker (CD20 on B cells, CD38 on plasma cells, CD30, CD33, CD22) and kill by recruiting immune cells and complement or by delivering an attached toxin (antibody-drug conjugates). Bispecific T-cell engagers bind CD3 on a T cell and a tumour marker (CD19, BCMA, CD20) at once, linking the two. CAR-T cells are the patient's own T cells, engineered to carry a chimeric antigen receptor against CD19 or BCMA, that multiply in the body. The more T cells are activated, the greater the risk of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
What to know
- Anti-CD20 (rituximab, obinutuzumab): B-cell lymphomas and CLL; infusion reactions, hepatitis B reactivation, low antibodies and infections.
- Anti-CD38 (daratumumab): myeloma; it binds the test red cells used in the antibody screen and makes them all look positive, so the blood bank must know before starting.
- Antibody-drug conjugates: brentuximab vedotin (CD30; nerve damage), gemtuzumab and inotuzumab ozogamicin (CD33 and CD22; liver sinusoidal obstruction).
- Bispecifics: blinatumomab (CD19 × CD3) for B-cell ALL, teclistamab (BCMA × CD3) for myeloma; CRS and neurotoxicity mostly with the first doses.
- CAR-T: CD19 for B-cell lymphomas and B-cell ALL (tisagenlecleucel, axicabtagene ciloleucel); BCMA for myeloma.
- CRS starts with fever, then low blood pressure and low oxygen, usually within days; ICANS causes confusion, word-finding difficulty, changes in handwriting, tremor, seizures and brain swelling, often during or after CRS.
How it is done (and why)
- CAR-T: collect the patient's T cells by apheresis; bridging treatment controls the cancer while the cells are made.
- The T cells are engineered in a laboratory to express the chimeric receptor and grown in large numbers.
- Lymphodepleting chemotherapy (fludarabine and cyclophosphamide) clears space so the CAR-T cells can expand.
- Infuse the cells and watch for fever, blood pressure, oxygen and neurological signs several times a day, with a simple writing and naming test.
- CRS: grade by fever, hypotension and hypoxia; give tocilizumab (anti-IL-6 receptor) and add steroids if severe, with supportive and ICU care.
- ICANS: steroids are the main treatment; seizure prevention and ICU care if severe; tocilizumab alone does not treat it.
- Afterwards: the patient stays near the treating centre for weeks, does not drive for a period, and is followed for low counts, infections and low antibodies.
Three ways to point the immune system at a blood cancer
| Feature | Monoclonal antibody | Bispecific T-cell engager | CAR-T cells |
|---|---|---|---|
| What it is | An antibody (sometimes carrying a toxin) against a tumour marker | A molecule binding CD3 on T cells and a tumour marker | The patient's T cells engineered with a new receptor |
| Who does the killing | Natural killer cells, macrophages, complement, or the toxin | The patient's own T cells, linked to the tumour | The engineered T cells, which multiply in the body |
| How it is given | Repeated infusions or injections | Repeated infusions or injections, stepped up at first | One infusion after lymphodepletion |
| Main early danger | Infusion reaction | CRS and neurotoxicity, mostly at the start | CRS and ICANS, often severe |
| Long-term effect | B-cell depletion with anti-CD20 | Low antibodies and infections | Long B-cell aplasia, low antibodies, prolonged low counts |
Risks and precautions
- Fever after CAR-T or a bispecific may be CRS, but the patient is often neutropenic: take cultures and start antibiotics while treating CRS.
- ICANS is found early by asking the patient to name objects, write a sentence and count backwards: a decline in handwriting or speech is an early sign.
- Screen for hepatitis B before anti-CD20 antibodies: reactivation can cause liver failure.
- Tell the blood bank before daratumumab and give a baseline group and screen: the interference can delay compatible blood.
- After CD19-directed therapy the B cells are gone for a long time: antibody levels fall and immunoglobulin replacement and infection prophylaxis may be needed.
Monitoring and next step
- Before treatment: count, kidney and liver tests, hepatitis B, hepatitis C and HIV, group and screen (before anti-CD38), and an immunoglobulin level.
- After CAR-T or bispecific: daily count, CRP and ferritin, kidney and liver tests, and coagulation; very high ferritin with falling counts suggests an HLH-like syndrome.
- Fever: blood cultures and a search for infection every time, even when CRS seems obvious.
- Neurological change: neurological exam and grading score, brain imaging and EEG if severe or seizures are suspected.
- Months later: immunoglobulin levels, count recovery and response assessment.
Common traps
- Treating fever after CAR-T as CRS alone: it may be neutropenic sepsis.
- Relying on tocilizumab for ICANS: it does not cross into the brain well; steroids are the treatment.
- Forgetting to warn the blood bank before daratumumab: the antibody screen is then unexplained and blood is delayed.
- Starting rituximab without hepatitis B screening: the screening comes first.
- Dismissing a small change in handwriting or speech after CAR-T: it can be the first sign of ICANS.
Test yourself
Think of the answer, then tap the question to see it.
Two days after CAR-T infusion a patient has a high fever, then low blood pressure. What is the likely syndrome, and what else must be excluded?
Cytokine release syndrome; infection must be excluded at the same time with cultures and antibiotics, since the patient is often neutropenic.
Why is tocilizumab not enough for a patient with ICANS but no CRS?
It blocks the IL-6 receptor in the blood but does not reach the brain well; steroids are the main treatment for ICANS.
Why does a myeloma patient on daratumumab have a positive antibody screen against every test cell?
Daratumumab binds CD38, which is also on the reagent red cells, so all test cells react; the blood bank uses special methods to find compatible blood.
What is the main difference between a bispecific T-cell engager and a CAR-T cell?
A bispecific is a drug that links the patient's existing T cells to the tumour and must be given repeatedly; CAR-T cells are engineered T cells given once that multiply.
Elsewhere in DurgiPedia
- Cancer immunotherapy: checkpoint inhibitors, CAR-T and vaccines
- Monoclonal antibodies and biologics: naming and targets
- Cytokine storm: CRS, HLH, sepsis and severe COVID-19
- How monoclonal antibodies are made: hybridomas to fully human
- Treating antibody diseases: IVIG, plasma exchange, B-cell depletion
Connections
Educational content; it does not replace assessment by a doctor or your institution's protocols. It contains no doses.
Sources: CAR T Cells: Engineering Patients’ Immune Cells to Treat Their Cancers (National Cancer Institute (NIH), 2024); Monoclonal Antibodies (National Cancer Institute (NCI), 2026); Blinatumomab Injection: MedlinePlus Drug Information (MedlinePlus (U.S. National Library of Medicine), 2024); Teclistamab-cqyv Injection: MedlinePlus Drug Information (MedlinePlus (U.S. National Library of Medicine), 2026).
Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake
Representative model, for educational purposes only.
